Tevogen Bio Holdings Inc. (TVGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.81 (+1.30%), Market cap $0.04B, 52-week low–high $0.19 ~ $9.42.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in p
Financial statements, price targets, institutional (13F) holdings and related news for Tevogen Bio Holdings Inc. are updated in real time on BlackAll Trade.
Tevogen Bio Holdings Inc. trades at $7.81 (+1.30%). Real-time quotes and charts are available on BlackAll Trade.
Tevogen Bio Holdings Inc. has a market cap of about $0.04B.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.